Synthetic community seed treatment for soybean sudden death syndrome control
Seed-applied synthetic community (SynCom) for controlling soybean Sudden Death Syndrome caused by Fusarium virguliforme. The approach combines direct antifungal antagonism with plant defense priming to suppress the pathogen and enhance systemic resistance in seedlings. Designed to be compatible with seed-applied fungicides, it aims to provide a sustainable alternative to synthetic fungicides while supporting plant and soil health.
Overview
This solution uses a Synthetic Community (SynCom) seed treatment to combat Sudden Death Syndrome (SDS) in soybeans caused by the soil-borne fungus Fusarium virguliforme. The SynCom approach leverages strains with antifungal and plant defense priming properties, compatible with seed-applied fungicides, to provide a dual mechanism of pathogen control: direct antagonism toward Fusarium through antimicrobial metabolite production and indirect induction of systemic resistance in soybean seedlings. The method is positioned as a sustainable alternative to synthetic SDHI fungicides and is intended to support plant and soil health, including enhancement of legume-Sinorhizobium symbiosis.
Technical specifications
- Direct Antagonism: SynCom strains produce antimicrobial metabolites that directly suppress Fusarium virguliforme.
- Systemic Resistance: The treatment primes soybean seedlings for enhanced systemic resistance against SDS.
- Compatibility: Works synergistically with commercial seed-coated fungicides such as fludioxonil and metalaxyl-M.
- Multifunctional Traits: Promotes plant growth, biofilm formation, and pathogen control.
- Sustainable Approach: Provides an eco-friendly alternative to traditional chemical fungicides.
Technology readiness level
Currently at Technology Readiness Level 4, the solution has undergone laboratory testing for strain antagonism and compatibility with fungicides. Initial tests show promising results in pathogen suppression and plant growth enhancement. Further validation and formulation development are planned to support commercial scalability.
About University of Delaware
The University of Delaware is a comprehensive public research university and the state’s flagship, recognized for cross-disciplinary collaboration with industry. A research and technology park adjacent to campus co-locates corporate R&D with university labs and startups, with shared facilities and pilot-scale capabilities; integration with a regional health system enables clinical translation. Its Mid-Atlantic location offers quick access to talent, transportation, and nearby industrial clusters, while a statewide extension network supports testing and adoption. Research is supported by competitive federal funding from agencies such as NSF, NIH, DOE, USDA, and NASA. A dedicated technology transfer office streamlines IP, licensing, and startup formation, and corporate engagement provides a single point of entry.
delivered to your inbox.